Literature DB >> 10338338

Naevus-associated melanomas: cause or chance?

D Massi1, P Carli, A Franchi, M Santucci.   

Abstract

Controversies exist regarding the true incidence and significance of the histological association between melanocytic naevi and melanomas. The current study was undertaken to determine the incidence of melanocytic naevi histologically associated with melanomas, to compare the clinicopathological profiles of melanomas associated with a naevus (MN+) and melanomas not associated with a naevus (MN-), and to verify the interobserver reliability of classifying the naevus remnants as congenital or acquired. We evaluated 131 patients with invasive melanoma < or = 4 mm in thickness with a Clark's level < V. Histological evidence of an associated melanocytic naevus was found in 27 out of 131 melanoma cases (20.6%). MN+ were significantly more frequent among males compared with MN-(P = 0.002) and were predominantly located on the trunk (P =0.001). No significant differences between MN+ and MN- were found in the distribution of histotype, Clark's level and thickness. Among MN-, the naevus component showed acquired features in 14 cases (51.8%), whereas 12 cases (44.5%) had features of small superficial congenital naevi; in one case (3.7%) a confident distinction between congenital and acquired naevus could not be made. Overall, there was concordance among the three observers in the diagnosis of the type of naevus remnants in 81.4% of cases (kappa = 0.78; P<0.0001). We conclude that, although the majority of cutaneous melanomas arise de novo, in approximately 20% of cases an associated melanocytic naevus is found. Our observation that MN+ and MN- have different clinicopathological profiles suggests that, at least for some cases, a causal relationship between the two lesions may be present. However, when the naevus is histopathologically adjacent to the melanoma, the possibility of a collision event cannot be ruled out. Finally, we documented a significant concordance among examiners in the diagnosis of the congenital versus acquired nature of the associated naevus. This suggests that the histopathological criteria generally employed to distinguish between congenital and acquired naevi have good reproducibility.

Entities:  

Mesh:

Year:  1999        PMID: 10338338     DOI: 10.1097/00008390-199902000-00011

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  6 in total

1.  Mutational status of naevus-associated melanomas.

Authors:  D Shitara; G Tell-Martí; C Badenas; M M S S Enokihara; L Alós; A B Larque; N Michalany; J A Puig-Butille; C Carrera; J Malvehy; S Puig; E Bagatin
Journal:  Br J Dermatol       Date:  2015-06-19       Impact factor: 9.302

2.  De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.

Authors:  Rachel M Cymerman; Yongzhao Shao; Kun Wang; Yilong Zhang; Era C Murzaku; Lauren A Penn; Iman Osman; David Polsky
Journal:  J Natl Cancer Inst       Date:  2016-05-27       Impact factor: 13.506

3.  Prevalence and clinical-pathological features of nevus-associated versus de novo melanoma: a retrospective cross-sectional study of 2806 cases.

Authors:  Michela Lai; Simonetta Piana; Giovanni Pellacani; Caterina Longo; Riccardo Pampena
Journal:  Dermatol Pract Concept       Date:  2022-04-01

4.  Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma.

Authors:  Brozyna Anna; Zbytek Blazej; Granese Jacqueline; Carlson J Andrew; Ross Jeffrey; Slominski Andrzej
Journal:  Expert Rev Dermatol       Date:  2007

Review 5.  Melanoma epidemiology and public health.

Authors:  Marianne Berwick; Esther Erdei; Jennifer Hay
Journal:  Dermatol Clin       Date:  2009-04       Impact factor: 3.478

6.  WLS inhibits melanoma cell proliferation through the β-catenin signalling pathway and induces spontaneous metastasis.

Authors:  Pei-Tzu Yang; Jamie N Anastas; Rachel A Toroni; Michi M Shinohara; Jamie M Goodson; Anja K Bosserhoff; Andy J Chien; Randall T Moon
Journal:  EMBO Mol Med       Date:  2012-11-06       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.